UB133
ProductHuman Albumin
Strength5g/vial (5%, 100mL); 5g/vial (20%, 25mL); 10g/vial (20%, 50mL); 12.5g/vial (25%, 50mL)
IndicationsHypovolaemic shock; Intracranial pressure increased; Oedema; Ascites; Hypoproteinaemia; Hyperbilirubinaemia neonatal; Cardiopulmonary bypass; Burn; Haemodialysis; Acute respiratory distress syndrome
TherapeuticsCardiovascular
GMPCN - NMPA
RegistrationChina
ModalitiesPeptide
Exclusive Summary
- - No patent barriers; as a mature plasma-derived product, it enables rapid registration and distribution entry in multiple markets.
- - Broad SKU coverage (5%, 20%, 25%; 5–12.5 g/vial) fits core use-cases like LVP, SBP, HRS, TPE and critical care albumin supplementation, reducing wastage.
- - Listed on the WHO Model List of Essential Medicines and strongly recommended by Western liver-disease guidelines for LVP/SBP/HRS, driving steady demand amid recurrent global shortages.
- - Competitive versus leading brands (Grifols/CSL/Octapharma/Takeda) in tenders by leveraging price and flexible supply.
- - Multi-pharmacopoeia alignment (JP/USP/EP/BP), established viral safety steps, and room-temperature shipping window (typically 2–25°C) support cross-border compliance and supply-chain efficiency.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →